Loading clinical trials...
Loading clinical trials...
An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis
Conditions
Interventions
Tralokinumab
Locations
29
United States
LEO Pharma Investigator
Birmingham, Alabama, United States
LEO Pharma Investigator
Birmingham, Alabama, United States
LEO Pharma Investigator
Fort Smith, Arkansas, United States
LEO Pharma Investigator
Fountain Valley, California, United States
LEO Pharma Investigator
Fremont, California, United States
LEO Pharma Investigational Site
Inglewood, California, United States
Start Date
January 13, 2022
Primary Completion Date
June 6, 2023
Completion Date
June 21, 2023
Last Updated
March 11, 2025
NCT06116526
NCT06461897
NCT07262983
NCT06389136
NCT06342713
NCT07290803
Lead Sponsor
LEO Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions